Nabiel Mir is an Oncology physician affiliated with University of Chicago. OpenAlex indexes 34 publications with 405 citations (h-index 10); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5841 S. Maryland Ave.
M/c 6098
Chicago, IL 606371443
Telephone
773-702-8840Provider last certified this registry record 9 Jul 2024.
Clinical trials
- Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
Sponsor: University of Chicago
- Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
Sponsor: University of Chicago
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
73.5%Angiotensin receptor blocker (ARB)26.5%Losartan Potassium100%Part D<11 patientsBeta blocker24.5%Carvedilol100%Part D<11 patients+ 1 more class in this area
Blood & clotting
26.5%Factor Xa inhibitor26.5%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
- ARTI-MPC – Activity, Risk & Therapy-Intensity in Metastatic Prostate Cancer
University of Chicago
FY2026$157,572K23AG101078
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Use of parsimonious Fitbit step metrics to improve frailty classification in adults ≥50 with cancer in NIH All of Us.
Journal of Clinical Oncology
2026 - Fitbit-derived activity and heart-rate patterns for predicting 12-month hospitalization in an NIH All of Us cancer cohort.
Journal of Clinical Oncology
2026 - Unique Opportunity and Motivational Targets for Exercise Behavior Change Among Nonfrail, Prefrail, and Frail Older Adults
Journal of Aging and Physical Activity
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Everett Vokes, MD
University of Chicago
Ralph Weichselbaum, MD
University of Chicago
Mary Rinella, MD
University of Chicago
Hedy Kindler, MD
University of Chicago
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”